Annika R. P. Schneider
YOU?
Author Swipe
View article: Harnessing Open‐Source Solutions: Insights From the First Open Systems Pharmacology (<scp>OSP</scp>) Community Conference
Harnessing Open‐Source Solutions: Insights From the First Open Systems Pharmacology (<span>OSP</span>) Community Conference Open
In 2017, the free and open‐source software Open Systems Pharmacology (OSP) was launched. Since then, OSP has evolved from a small community into a diverse network of stakeholders committed to advancing open‐source solutions for model‐infor…
View article: A Comprehensive <scp>CYP2D6</scp> Drug–Drug–Gene Interaction Network for Application in Precision Dosing and Drug Development
A Comprehensive <span>CYP2D6</span> Drug–Drug–Gene Interaction Network for Application in Precision Dosing and Drug Development Open
Conducting clinical studies on drug–drug‐gene interactions (DDGIs) and extrapolating the findings into clinical dose recommendations is challenging due to the high complexity of these interactions. Here, physiologically‐based pharmacokinet…
View article: Population pharmacokinetic–pharmacodynamic model of elinzanetant based on integrated clinical phase I and II data
Population pharmacokinetic–pharmacodynamic model of elinzanetant based on integrated clinical phase I and II data Open
Elinzanetant is a potent and selective dual neurokin‐1 (NK‐1) and ‐3 (NK‐3) receptor antagonist that is currently developed for the treatment of women with moderate‐to‐severe vasomotor symptoms (VMS) associated with menopause. Here, we rep…
View article: Early prediction of decompensation (<scp>EPOD</scp>) score: Non‐invasive determination of cirrhosis decompensation risk
Early prediction of decompensation (<span>EPOD</span>) score: Non‐invasive determination of cirrhosis decompensation risk Open
Background & Aims Decompensation is a hallmark of disease progression in cirrhotic patients. Early detection of a phase transition from compensated cirrhosis to decompensation would enable targeted therapeutic interventions potentially ext…
View article: A Model‐Based Workflow to Benchmark the Clinical Cholestasis Risk of Drugs
A Model‐Based Workflow to Benchmark the Clinical Cholestasis Risk of Drugs Open
We present a generic workflow combining physiology‐based computational modeling and in vitro data to assess the clinical cholestatic risk of different drugs systematically. Changes in expression levels of genes involved in the enterohepati…
View article: Data‐driven personalization of a physiologically based pharmacokinetic model for caffeine: A systematic assessment
Data‐driven personalization of a physiologically based pharmacokinetic model for caffeine: A systematic assessment Open
Physiologically based pharmacokinetic (PBPK) models have been proposed as a tool for more accurate individual pharmacokinetic (PK) predictions and model‐informed precision dosing, but their application in clinical practice is still rare. T…